-c-mudit-mathur-jpg
(c)Mudit Mathur
9 July 2015AsiaYuanqiong Hu

Under pressure: India’s progressive IP policies

India, with its progressive public health policies and patent laws, has long been known as the ‘pharmacy of the developing world’. With good reason: more than 96% of the antiretroviral medicines used to treat HIV purchased by donors for developing country treatment programmes are Indian-sourced generics. At Médecins Sans Frontières (MSF), we rely heavily on Indian generics to support the treatment of more than 200,000 people living with HIV/AIDS.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
22 June 2026   The court granted Blue Cross Laboratories a permanent injunction after finding that a rival product’s mark and packaging closely mirrored its own.
Asia
27 May 2026   China’s IP system is undergoing real change. Takeda’s IP head for the region explains what that looks like on the ground and why the old playbook no longer cuts it.
Asia
24 May 2026   The regulatory and IP environment in China is shifting at a rapid pace, bringing new measures, guiding cases, and compliance hurdles. This session provides a high-level overview of the past year’s critical changes and what life sciences companies must anticipate on the horizon.